Loading clinical trials...
Loading clinical trials...
Dialysis Adequacy and Clotting Complications During Anticoagulation-free Hemodialysis Using a Heparin-grafted Dialyzer and a Citrate-enriched Dialysate: a Prospective Randomized Crossover Study. (EvoCit-HD Study)
After providing informed consent, patients will be randomized to either the intervention treatment ("EvoCit procedure") or the control treatment ("EvoHep procedure"). After randomization, each study arm consists of four weeks of 3x4 hours hemodialysis treatments according to the allocated protocol. After the last dialysis treatment of the fourth treatment week and after a long interdialytic interval, patients will crossover to the alternative hemodialysis procedure. After crossover, the study will be completed with, again, four weeks of 3x4 hours hemodialysis treatments according to the allocated protocol.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
UZ Brussel
Jette, Belgium
CHU Brugmann
Laken, Belgium
Start Date
May 15, 2018
Primary Completion Date
December 4, 2019
Completion Date
December 4, 2019
Last Updated
January 18, 2020
38
ACTUAL participants
EvoCit
DEVICE
EvoHep
DEVICE
Lead Sponsor
Universitair Ziekenhuis Brussel
NCT06656988
NCT04592640
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions